951745-01-0

Basic information

• Product Name: N-Boc-4-MethylpiperidinecarbothioaMide
• Synonyms: N-Boc-4-MethylpiperidinecarbothioaMide;4-Methyl-4-thiocarbaMoylpiperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 951745-01-0
• Molecular Formula: C₁₂H₂₂N₂O₂S
• Molecular Weight: 258
• Mol File: 951745-01-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-Boc-4-MethylpiperidinecarbothioaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-4-MethylpiperidinecarbothioaMide(951745-01-0)
• EPA Substance Registry System: N-Boc-4-MethylpiperidinecarbothioaMide(951745-01-0)

Safety Data

• Hazardous Substances Data: 951745-01-0(Hazardous Substances Data)

Usage

General Description

N-Boc-4-Methylpiperidinecarbothioamide is a chemical compound that belongs to the class of piperidines. It is commonly used as a reagent in organic synthesis and pharmaceutical research. N-Boc-4-MethylpiperidinecarbothioaMide is known for its potential applications in the production of pharmaceutical drugs and agrochemicals. N-Boc-4-Methylpiperidinecarbothioamide is also used as a building block in the synthesis of various bioactive compounds and is valued for its versatile nature in chemical reactions. It is important to handle this chemical with care and adhere to proper safety protocols when working with it in a laboratory setting.

Upstream product

• 343788-67-0 4-carbamoyl-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 91419-52-2 1-tert-butoxycarbonyl-4-cyanopiperidine 
• 530115-96-9 4-cyano-4-methylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1037792-97-4 4-[4-(4-methanesulfonylphenoxymethyl)thiazol-2-yl]-4-methylpiperidine-1-carboxylic acid tert-butyl ester 
• 1195769-66-4 1,1-dimethylethyl 4-[5-(2-amino-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-4-methyl-1-piperidinecarboxylate 
• 1195769-64-2 1,1-dimethylethyl 4-[5-(2-chloro-4-pyrimidinyl)-4-(3-{[(2,6-difluorophenyl)sulfonyl]amino}-2-fluorophenyl)-1,3-thiazol-2-yl]-4-methyl-1-piperidinecarboxylate 
• 1195769-67-5 1,1-dimethylethyl 4-(5-(2-chloro-4-pyrimidinyl)-4-{2-fluoro-3-[(3-furanylsulfonyl)amino]phenyl}-1,3-thiazol-2-yl)-4-methyl-1-piperidinecarboxylate 
• 1195769-68-6 1,1-dimethylethyl 4-(5-(2-amino-4-pyrimidinyl)-4-{2-fluoro-3-[(3-furanylsulfonyl)amino]phenyl}-1,3-thiazol-2-yl)-4-methyl-1-piperidinecarboxylate 
• 1195768-01-4 N-{3-[5-(2-amino-4-pyrimidinyl)-2-(4-methyl-4-piperidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-3-furansulfonamide 
• 1195769-62-0 1,1-dimethylethyl 4-[5-(2-chloro-4-pyrimidinyl)-4-(2-fluoro-3-{[(2-propen-1-yloxy)carbonyl]amino}phenyl)-1,3-thiazol-2-yl]-4-methyl-1-piperidinecarboxylate 
• 1307271-96-0 1,1-dimethylethyl 4-(4-{2-fluoro-3-[(propylsulfonyl)amino]phenyl}-5-{2-[(2-hydroxyethyl)amino]-4-pyrimidinyl}-1,3-thiazol-2-yl)-4-methyl-1-piperidinecarboxylate 
• 1307271-95-9 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(1,4-dimethyl-4-piperidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-1-propanesulfonamide trifluoroacetate 
• 1307271-93-7 N-{3-[5-(2-chloro-4-pyrimidinyl)-2-(4-methyl-4-piperidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-1-propanesulfonamide 
• 1307271-92-6 1,1-dimethylethyl 4-(5-(2-amino-4-pyrimidinyl)-4-{2-fluoro-3-[(propylsulfonyl)amino]phenyl}-1,3-thiazol-2-yl)-4-methyl-1-piperidinecarboxylate 
• 1307271-91-5 1,1-dimethylethyl 4-(5-(2-chloro-4-pyrimidinyl)-4-{2-fluoro-3-[(propylsulfonyl)amino]phenyl}-1,3-thiazol-2-yl)-4-methyl-1-piperidinecarboxylate 
• 1307271-89-1 N-{3-[5-(2-amino-4-pyrimidinyl)-2-(4-methyl-4-piperidinyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-1-propanesulfonamide 
• 1307271-30-2 N-{2-fluoro-3-[5-{2-[(2-hydroxyethyl)amino]-4-pyrimidinyl}-2-(4-methyl-4-piperidinyl)-1,3-thiazol-4-yl]phenyl}-1-propanesulfonamide 

Relevant articles and documents

OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS

Use of oxymethylene aryl GPRl 19 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provide

HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.